Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 28;10(5):783-785.
doi: 10.14218/JCTH.2022.00229. Epub 2022 Jul 29.

Therapeutic Use of Viruses: Newcastle Disease Virus HK84 Oncolytic Treatment for Hepatocellular Carcinoma

Leonardo Baiocchi  1 , Heather Francis  2   3 , Gianfranco Alpini  2   3
Affiliations

Therapeutic Use of Viruses: Newcastle Disease Virus HK84 Oncolytic Treatment for Hepatocellular Carcinoma

Leonardo Baiocchi et al. J Clin Transl Hepatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

GA and HF have been editorial board members of Journal of Clinical and Translational Hepatology since 2013. LB has no conflict of interests related to this publication.

Figures

Fig. 1
Fig. 1. Effects of drugs used in hepatocellular carcinoma and those possibly associated with oncolytic viral therapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Haber PK, Puigvehi M, Castet F, Lourdusamy V, Montal R, Tabrizian P, et al. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020) Gastroenterology. 2021;161(3):879–898. doi: 10.1053/j.gastro.2021.06.008. - DOI - PubMed
    1. Sangro B, Sarobe P, Hervas-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543. doi: 10.1038/s41575-021-00438-0. - DOI - PMC - PubMed
    1. Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic Viruses in Cancer Treatment: A Review. JAMA Oncol. 2017;3(6):841–849. doi: 10.1001/jamaoncol.2016.2064. - DOI - PubMed
    1. Geoffroy K, Bourgeois-Daigneault MC. The pros and cons of interferons for oncolytic virotherapy. Cytokine Growth Factor Rev. 2020;56:49–58. doi: 10.1016/j.cytogfr.2020.07.002. - DOI - PubMed
    1. Chen L, Niu Y, Sun J, Lin H, Liang G, Xiao M, et al. Oncolytic Activity of Wild-type Newcastle Disease Virus HK84 Against Hepatocellular Carcinoma Associated with Activation of Type I Interferon Signaling. J Clin Transl Hepatol. 2022;10(2):284–296. doi: 10.14218/JCTH.2021.00284. - DOI - PMC - PubMed